Compare Chevron Corp (CVX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Pfizer Inc — how do they compare? Chevron Corp trades at $212.13 (market cap $414.98B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: Chevron Corp is far larger — about 2.6× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Pfizer Inc for 158 Days on average.
| CVX | PFE | |
|---|---|---|
Market Cap | $414.98B | $158.56B |
Volume | 7,575,112 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $217.73 | $29.02 |
52-Week Low | $146.72 | $23.67 |
Typical Hold Time | 101 Days | 158 Days |
Enterprise Value | $443.52B | $210.06B |
Dividend Yield | 3.37% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $205.19, down 1.17% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. Revenue declined to $184.43B in 2025, but a rebound to $208.7B is projected for 2026. Analyst consensus is a Buy with a $208.31 price target, and the company maintains a strong balance sheet with $6.79B in cash.
CVX presents a mixed outlook; earnings beats and a favorable analyst consensus support upside, but declining revenue and net income margins pose risks. High oil prices and strategic investments, like the $13.8B Argentina project, offer growth potential, yet geopolitical tensions and volatile energy markets remain headwinds for shareholders.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
